Topics

GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) Company Profile

13:20 EDT 21st September 2019 | BioPortfolio

The MECTIZAN® Donation Program (MDP) was established in 1987 to provide medical, technical and administrative oversight of the donation of MECTIZAN® by MSD for the treatment of onchocerciasis. In 1998, MDP expanded its mandate to include oversight of the donation of albendazole by GSK for the elimination of lymphatic filariasis in onchocerciasis co-endemic areas.


News Articles [2046 Associated News Articles listed on BioPortfolio]

Merck to build new plant in N.C.

Merck Sharp and Dohme will invest some $680 million in new manufacturing space and expanded packaging space to support its HPV vaccine Gardisil.

Merck’s V114 yields positive data in pneumococcal disease

Merck Sharp & Dohme has reported positive results from the Phase II clinical trial of its investigational 15-valent pneumococcal conjugate...Read More... The post Merck’s V114 yields positive da...

Merck’s Belsomra achieves Phase III efficacy endpoints for insomnia

Merck Sharp & Dohme has reported that a Phase III clinical trial of Belsomra (suvorexant) C-IV has met the primary...Read More... The post Merck’s Belsomra achieves Phase III efficacy endpoints ...

Merck increases measles vaccine production amid outbreak in US

Merck Sharp & Dohme (MSD) has increased the production of its measles vaccine in the US to meet a rise...Read More... The post Merck increases measles vaccine production amid outbreak in US appear...

Wechsel an der Spitze bei Werthenstein BioPharma GmbH, der R&D-Einheit von MSD Merck Sharp & Dohme AG

Luzern (ots) - - Hinweis: Hintergrundinformationen können kostenlos im pdf-Format unter http://presseportal.ch/de/nr/100053016 heruntergeladen werden - - Hinweis: Bildmaterial wird via KEYSTONE-Ne...

Five hepatitis C drugs to become available on the NHS

A deal signed by pharmaceutical companies AbbVie, Gilead Sciences and Merck Sharp and Dohme (MSD) will see five new hepatitis...Read More... The post Five hepatitis C drugs to become available on the ...

Par launches authorized generic Noxafil

Mayne Cannot Revive US Antifungals Patent

A late disclosure of interest for its parent group should not prevent Merck Sharp & Dohme from knocking down Mayne...   

Drugs and Medications [146 Associated Drugs and Medications listed on BioPortfolio]

Sylatron [merck sharp & dohme corp.]

These highlights do not include all the information needed to use SYLATRON safely and effectively. See full prescribing information for SYLATRON. SYLATRON™ (peginterferon alfa-2b) for injection, for...

Guanidine hydrochloride [merck sharp & dohme corp.]

GUANIDINEHYDROCHLORIDETablets

Rebetol [merck sharp & dohme corp.]

These highlights do not include all the information needed to use REBETOL safely and effectively. See full prescribing information for REBETOL.REBETOL (ribavirin USP) capsules, for oral use REBETOL (r...

Pregnyl [organon usa inc.]

Pregnyl (chorionic gonadotropin for injection USP)

Dificid [merck sharp & dohme corp.]

These highlights do not include all the information needed to use DIFICID safely and effectively. See full prescribing information for DIFICID. DIFICID (fidaxomicin) tablets, for oral useInitial U.S. ...

PubMed Articles [1158 Associated PubMed Articles listed on BioPortfolio]

Patient Perspectives on Weight Management for Living Kidney Donation.

Living kidney donors (LKDs) with obesity have increased perioperative risks and risk of end-stage renal disease after donation. Consequently, obesity serves as a barrier to donation, as many transplan...

Uncontrolled donation after circulatory death: ethics of implementation.

Despite its potential to increase the donor pool, uncontrolled donation after circulatory death (uDCD) is available in a limited number of countries. Ethical concerns may preclude the expansion of thi...

Evaluation of the quality of the communication and emotional support during the donation procedure: The use of the donor family questionnaire (DFQ).

A multi-centric study in Intensive Care units (ICU) and Emergency departments (ED) was designed to evaluate whether the provided communication and emotional support to the family in the context of org...

Does organ donation impact on forensic outcomes? A review of coronial outcomes and criminal trial proceedings.

Despite increases in organ donation rates, there continue to be waiting lists for patients in urgent need of transplantation. Where a death occurs under a number of specific circumstances, donation ca...

Religious and Cultural Aspects of Organ Donation in the Turkish Population.

Organ donation is becoming more important with increasing organ transplantation possibilities. We aimed to determine the knowledge, sociocultural view, and influences of religious belief regarding opi...

Clinical Trials [4661 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets

To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.

Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting Conditions

This is an open-label, randomized, single-center, single-dose, crossover, in two periods and in two sequences comparative study, where each participant is randomly assigned to the referenc...

Alendronate Sodium 70 mg Tablet Versus Fosamax® Under Fasting Conditions.

The objective of this study is to compare the rate and extent of absorption of alendronate sodium 70 mg tablets (test) versus Fosamax® 70 mg tablets (reference) administered as a single d...

Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

The present study was a randomized, open-label, two-period, two-sequence, cross-over study, conducted to find out whether the etoricoxib 120 mg film-coated tablet produced by PT Dexa Medic...

The Paired Donation Consortium Paired Donation Program

The purpose of the protocol is to increase the number of living donor transplants by eliminating immune incompatibilities between donors and recipients through paired donation.

Companies [1080 Associated Companies listed on BioPortfolio]

GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP)

The MECTIZAN® Donation Program (MDP) was established in 1987 to provide medical, technical and administrative oversight of the donation of MECTIZAN® by MSD for the treatment...

Merck and Cardiome Pharma Corp.

In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck, Sharp and...

Merck Sharpe and Dohme

Pharmanex

A Story of Innovation, Commitment to Excellence and Determination to Better People's LivesA leading pharmaceutical scientist, Dr. Michael Chang first conceived Pharmanex in 1994. His vision was to cre...

The Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company an...

More Information about "GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP)" on BioPortfolio

We have published hundreds of GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) news stories on BioPortfolio along with dozens of GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) Clinical Trials and PubMed Articles about GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) Companies in our database. You can also find out about relevant GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) Drugs and Medications on this site too.

Quick Search

Relevant Topic

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...


Corporate Database Quicklinks



Searches Linking to this Company Record